Venturi Wealth Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-1,557
Closed -$269K 642
2026
Q1
$269K Sell
1,557
-99
-6% -$18.4K 0.01% 501
2025
Q4
$330K Buy
1,656
+119
+8% +$21.6K 0.01% 440
2025
Q3
$240K Buy
+1,537
New +$244K 0.01% 495
2025
Q2
Sell
-2,315
Closed -$348K 546
2025
Q1
$348K Sell
2,315
-2,052
-47% -$344K 0.02% 409
2024
Q4
$806K Buy
4,367
+2,751
+170% +$530K 0.04% 239
2024
Q3
$318K Buy
1,616
+614
+61% +$128K 0.02% 378
2024
Q2
$207K Buy
1,002
+754
+304% +$171K 0.01% 403
2024
Q1
$67.2K Hold
248
﹤0.01% 465
2023
Q4
$58.6K Sell
248
-14
-5% -$2.75K ﹤0.01% 473
2023
Q3
$51.3K Buy
262
+112
+75% +$23K ﹤0.01% 467
2023
Q2
$31.5K Buy
150
+28
+23% +$5.57K ﹤0.01% 483
2023
Q1
$24.6K Buy
+122
New +$27.6K ﹤0.01% 560

Other funds holding CRL

Venturi Wealth Management's CRL Position: Q2 2026 in Review

Venturi Wealth Management sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 1,557 shares — an estimated $269K sold.

Venturi Wealth Management first reported a position in CRL in Q1 2023 and held it in 12 quarters. The position peaked at $806K in Q4 2024. 81 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Venturi Wealth Management reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • Venturi Wealth Management sold 1,557 Charles River Laboratories shares in Q2 2026, an estimated $269K.
  • Venturi Wealth Management first reported a position in Charles River Laboratories in Q1 2023 and held it in 12 quarters.
  • Venturi Wealth Management's Charles River Laboratories position peaked at $806K in Q4 2024.
  • 81 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Venturi Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.